drugset / Trial / NCT01821066

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

NCT01821066

Phase 1 Completed 25 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

A single 125 mg oral dose of the investigational compound PD-0332991 will be administered alone and after steady-state dosing of tamoxifen to determine if coadministration of tamoxifen alters the plasma pharmacokinetics of PD-0332991 in healthy male volunteers.

Timeline

Start
2013-04
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule 125 mg Oral
Subject Tamoxifen Small molecule 20 mg Oral

Indications

No indication recorded.